SCHEMBL14294429

SCHEMBL14294429

[N-]=[N+]=NCCCc1ccc(N=O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRB2 P07550 2/20 0.41
▸ PDPK1 O15530 1/20 0.36
▸ CA2 P00918 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ HTR3A P46098 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.31
▸ HSD17B10 Q99714 2/20 0.31
▸ TP53 P04637 2/20 0.31
▸ TSHR P16473 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ HIF1A Q16665 1/20 0.31
▸ LOX P28300 1/20 0.31
▸ MIF P14174 1/20 0.31
▸ P2RY6 Q15077 1/20 0.31
▸ CYP3A4 P08684 1/20 0.30
▸ CYP2D6 P10635 1/20 0.30
▸ CYP2C9 P11712 1/20 0.30
▸ HDAC3 O15379 1/20 0.30
▸ HDAC1 Q13547 1/20 0.30
▸ HDAC2 Q92769 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13527310 0.95 ADRB2 (0.42) ADRB2PDPK1CA2CA9ALDH1A1
SCHEMBL14295127 0.89 CA2 (0.34) ADRB2PDPK1CA2CA9ALDH1A1
SCHEMBL21084402 0.86 ADRB2 (0.48) ADRB2PDPK1CA2CA9HTR3A
SCHEMBL14048731 0.80 ALDH1A1 (0.35) HTR3AALDH1A1HSD17B10TP53TSHR
SCHEMBL16674489 0.80 ADRB2 (0.49) ADRB2PDPK1ALDH1A1HSD17B10TP53
SCHEMBL13608769 0.79 ADRB2 (0.47) ADRB2PDPK1
SCHEMBL14294476 0.79 HDAC3 (0.41) ALDH1A1HSD17B10TP53TSHRMAPK1
SCHEMBL25232794 0.77 HTR3E (0.48) ADRB2HTR3AMIFHDAC3HDAC1
SCHEMBL14937214 0.77 ESR1 (0.50) ADRB2CA2HTR3AALDH1A1HSD17B10
SCHEMBL16212606 0.77 MAOB (0.50) ADRB2PDPK1HTR3AALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120252747-A1 MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME SILICON VALLEY BANK 2012-10-04 — — US disclosed
US-8202843-B2 Macrocyclic compounds and methods of making and using the same RIB-X PHARMACEUTICALS, INC. (US) 2012-06-19 — — US disclosed
US-20080045585-A1 Macrocyclic Compounds And Methods Of Making And Using The Same BioVersys AG (CH) 2008-02-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252747-A1 MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME CCNO, PTGDR, CCNE1 ADRB2 2758/4885PDPK1 3185/4885CA2 2606/4885
US-20080045585-A1 Macrocyclic Compounds And Methods Of Making And Using The Same VIP, PROKR1, PGC ADRB2 4099/4885PDPK1 1913/4885CA2 3768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback